<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR26.html">Part 26
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 26.47  Role and composition of the Joint Sectoral Committee.
                            </h3>
                            <p class="depth1"><em>(a)</em> The Joint Sectoral Committee for this subpart is set up to  monitor the activities under both the transitional and operational  phases of this subpart.</p><p class="depth1"><em>(b)</em> The Joint Sectoral Committee will be cochaired by a  representative of the Food and Drug Administration (FDA) for the United  States and a representative of the European Community (EC) who will each  have one vote. Decisions will be taken by unanimous consent.</p><p class="depth1"><em>(c)</em> The Joint Sectoral Committee's functions will include:</p><p class="depth2"><em>(1)</em> Making a joint assessment of the equivalence of conformity  assessment bodies (CAB's);</p><p class="depth2"><em>(2)</em> Developing and maintaining the list of equivalent CAB's,  including any limitation in terms of their scope of activities and  communicating the list to all authorities and the Joint Committee  described in subpart C of this part;</p><p class="depth2"><em>(3)</em> Providing a forum to discuss issues relating to this subpart,  including concerns that a CAB may no longer be equivalent and  opportunity to review product coverage; and</p><p class="depth2"><em>(4)</em> Consideration of the issue of suspension.</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
